RGTLF (Argent Biopharma) Ending Cash Position: $1.02 Mil (As of Dec. 2025)


What is Argent Biopharma Ending Cash Position?

Argent Biopharma RGTLF Ending Cash Position is $1.02 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Argent Biopharma's Ending Cash Position for the quarter that ended in Dec. 2025 was $1.02 Mil.

Argent Biopharma's quarterly Ending Cash Position increased from Dec. 2024 ($0.46 Mil) to Jun. 2025 ($0.67 Mil) and increased from Jun. 2025 ($0.67 Mil) to Dec. 2025 ($1.02 Mil).

Argent Biopharma's annual Ending Cash Position increased from Jun. 2023 ($0.16 Mil) to Jun. 2024 ($0.47 Mil) and increased from Jun. 2024 ($0.47 Mil) to Jun. 2025 ($0.67 Mil).

Argent Biopharma Ending Cash Position Related Terms

Argent Biopharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Argent Biopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Ending Cash Position Chart

Argent Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.15 1.24 0.16 0.47 0.67

Argent Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.34 0.47 0.46 0.67 1.02

Argent Biopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Argent Biopharma's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.458+0.209
=0.67

Argent Biopharma's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.681+0.335
=1.02

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.02 Mil mean?
Argent Biopharma (RGTLF) has a Ending Cash Position of $1.02 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Argent Biopharma and its competitors.
Is Argent Biopharma's Ending Cash Position too high?
Argent Biopharma's current Ending Cash Position is $1.02 Mil.
How does Argent Biopharma's Ending Cash Position compare to ZTS and UTHR?
Argent Biopharma's Ending Cash Position of $1.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Argent Biopharma and its competitors. Argent Biopharma's current Ending Cash Position is $1.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Ending Cash Position is $1.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Ending Cash Position is $1.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.